BCAB
Price
$0.15
Change
-$0.01 (-6.25%)
Updated
Feb 13 closing price
Capitalization
11.23M
33 days until earnings call
Intraday BUY SELL Signals
CDXS
Price
$1.20
Change
+$0.02 (+1.69%)
Updated
Feb 13 closing price
Capitalization
108.39M
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCAB vs CDXS

Header iconBCAB vs CDXS Comparison
Open Charts BCAB vs CDXSBanner chart's image
BioAtla
Price$0.15
Change-$0.01 (-6.25%)
Volume$1.9M
Capitalization11.23M
Codexis
Price$1.20
Change+$0.02 (+1.69%)
Volume$1.38M
Capitalization108.39M
BCAB vs CDXS Comparison Chart in %
BCAB
Daily Signal:
Gain/Loss:
CDXS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCAB vs. CDXS commentary
Feb 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a StrongBuy and CDXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 15, 2026
Stock price -- (BCAB: $0.15 vs. CDXS: $1.20)
Brand notoriety: BCAB and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAB: 72% vs. CDXS: 127%
Market capitalization -- BCAB: $11.23M vs. CDXS: $108.39M
BCAB [@Biotechnology] is valued at $11.23M. CDXS’s [@Biotechnology] market capitalization is $108.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $124.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 1 green FA rating(s).

  • BCAB’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 1 green, 4 red.
According to our system of comparison, CDXS is a better buy in the long-term than BCAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 5 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • BCAB’s TA Score: 5 bullish, 4 bearish.
  • CDXS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BCAB is a better buy in the short-term than CDXS.

Price Growth

BCAB (@Biotechnology) experienced а -28.77% price change this week, while CDXS (@Biotechnology) price change was -9.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.41%. For the same industry, the average monthly price growth was -4.89%, and the average quarterly price growth was +22.89%.

Reported Earning Dates

BCAB is expected to report earnings on Mar 19, 2026.

CDXS is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+2.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXS($108M) has a higher market cap than BCAB($11.2M). CDXS YTD gains are higher at: -26.380 vs. BCAB (-73.578). CDXS has higher annual earnings (EBITDA): -55.32M vs. BCAB (-65.71M). CDXS has more cash in the bank: 58.7M vs. BCAB (8.32M). BCAB has less debt than CDXS: BCAB (6.18M) vs CDXS (68.6M). CDXS has higher revenues than BCAB: CDXS (52.9M) vs BCAB (0).
BCABCDXSBCAB / CDXS
Capitalization11.2M108M10%
EBITDA-65.71M-55.32M119%
Gain YTD-73.578-26.380279%
P/E RatioN/AN/A-
Revenue052.9M-
Total Cash8.32M58.7M14%
Total Debt6.18M68.6M9%
FUNDAMENTALS RATINGS
CDXS: Fundamental Ratings
CDXS
OUTLOOK RATING
1..100
54
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCABCDXS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 24 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCAB
Daily Signal:
Gain/Loss:
CDXS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WSR15.210.21
+1.40%
Whitestone REIT
DOV231.631.06
+0.46%
Dover Corp
PJT154.240.13
+0.08%
PJT Partners
APYX3.72-0.10
-2.62%
Apyx Medical Corp
AIMD1.52-0.06
-3.80%
AINOS Inc

BCAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been closely correlated with VTGN. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if BCAB jumps, then VTGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
-8.93%
VTGN - BCAB
82%
Closely correlated
-7.23%
TPST - BCAB
80%
Closely correlated
+2.16%
MREO - BCAB
80%
Closely correlated
-4.32%
RZLT - BCAB
77%
Closely correlated
+5.79%
CALC - BCAB
77%
Closely correlated
-6.41%
More

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been closely correlated with ARTV. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDXS jumps, then ARTV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+1.69%
ARTV - CDXS
70%
Closely correlated
+0.25%
VTGN - CDXS
68%
Closely correlated
-7.23%
LENZ - CDXS
68%
Closely correlated
-0.69%
BCAB - CDXS
67%
Closely correlated
-8.93%
ARCT - CDXS
67%
Closely correlated
+0.56%
More